

Ribavirin and IVIG Therapy for Severe hMPV Pneumonia: A Promising Therapeutic Approach for India



Shambo S Samajdar¹, Rupak Chatterjee^{2*}, Shatavisa Mukherjee³, Nandini Chatterjee⁴, Jyotirmoy Pal⁵, Mangesh Tiwaskar⁶, Shashank Joshi⁷

Received: 02 February 2025; Accepted: 17 March 2025

ABSTRACT

Human metapneumovirus (hMPV) is a leading cause of acute respiratory tract infections (ARTIs), with severe cases predominantly affecting immunocompromised individuals, such as transplant recipients, cancer patients, and those with chronic illnesses. In these high-risk populations, hMPV pneumonia often leads to prolonged hospitalization and elevated mortality rates.

While supportive care remains the cornerstone of hMPV management, targeted therapies are urgently needed. Ribavirin, a broad-spectrum antiviral, combined with intravenous immunoglobulin (IVIG), has shown potential in reducing disease severity and improving outcomes in immunocompromised patients. This manuscript synthesizes the clinical evidence for ribavirin–IVIG therapy, discusses its mechanisms of action, and highlights its relevance in the Indian healthcare context, where respiratory infections impose a significant burden.

Despite its promise, challenges such as high costs, limited awareness among clinicians, and logistical barriers restrict the adoption of ribavirin–IVIG in India. This review emphasizes the need for multicenter trials to establish efficacy, optimize dosing, and evaluate cost effectiveness in resource-limited settings. By addressing these gaps, ribavirin–IVIG therapy could play a transformative role in reducing the morbidity and mortality associated with severe hMPV pneumonia.

Journal of The Association of Physicians of India (2025); 10.59556/japi.73.1100

INTRODUCTION

Human metapneumovirus (hMPV), first described in 2001, has emerged as a significant etiological agent of acute respiratory tract infections (ARTIs) worldwide, particularly in vulnerable populations.¹ While the majority of hMPV infections present with mild symptoms, immunocompromised individuals—such as transplant recipients, cancer patients undergoing chemotherapy, and individuals with chronic illnesses—are at increased risk of severe complications. These complications often necessitate prolonged hospital stays and are associated with elevated mortality rates, underscoring the clinical impact of hMPV in high-risk groups.²

Despite the substantial burden posed by hMPV, the management of severe cases remains largely supportive, with no universally approved antiviral treatment available. Ribavirin, a broad-spectrum antiviral agent, has shown promise in reducing disease severity when combined with intravenous immunoglobulin (IVIG), which enhances passive immunity. This therapeutic combination has been particularly beneficial in patients with compromised immune systems, as evidenced by case studies and limited clinical trials.³

This manuscript aims to provide a comprehensive review of the clinical

evidence supporting ribavirin and IVIG as a targeted therapeutic option for severe hMPV pneumonia. It also examines the underlying mechanisms of action and highlights the relevance of this approach within the Indian healthcare context, where respiratory infections remain a leading cause of morbidity and mortality in immunosuppressed populations. By addressing the gaps in current treatment protocols, we aim to underscore the need for tailored therapeutic strategies and the potential for this combination therapy to improve outcomes in resource-constrained settings.

CLINICAL EVIDENCE SUPPORTING RIBAVIRIN–IVIG COMBINATION THERAPY

The use of ribavirin and IVIG as a therapeutic combination for severe hMPV infections has shown promising results in specific high-risk populations. A notable case report documented the recovery of a 2-year-old child with Burkitt lymphoma and life-threatening hMPV pneumonia following treatment with ribavirin and IVIG after failure of conventional supportive care. This case highlights the potential for targeted antiviral and immunomodulatory therapies to

improve outcomes in immunocompromised patients.⁴

In addition, a retrospective multicenter study demonstrated significantly improved survival rates among hematopoietic stem cell transplant recipients who received ribavirin–IVIG therapy compared to those who received only supportive care. This finding underscores the potential role of this combination in reducing mortality in patients at the highest risk for severe hMPV-related complications.⁵

Furthermore, meta-analyses of available evidence have revealed that the ribavirin–IVIG combination can substantially reduce hospitalization duration and mortality in high-risk groups, particularly among immunosuppressed individuals and those with underlying malignancies. These findings collectively support the therapeutic potential of ribavirin and IVIG for managing severe hMPV infections.⁶

MECHANISMS OF ACTION

Ribavirin

Ribavirin acts as a broad-spectrum antiviral agent by inhibiting viral ribonucleic acid (RNA) polymerase, effectively suppressing hMPV replication. Additionally, ribavirin

¹Clinical Pharmacologist & Consultant, Diabetes & Allergy–Asthma Therapeutics Specialty Clinic;

²Senior Resident, Department of Medicine, Calcutta National Medical College & Hospital

³Research Associate, Department of Clinical Pharmacology, School of Tropical Medicine;

⁴Professor, Department of Medicine, Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital;

⁵Professor, Department of Medicine, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal; ⁶Consultant Physician and Diabetologist, Shilpa Medical Research Centre;

⁷Consultant Endocrinologist, Joshi Clinic, Mumbai, Maharashtra, India; *Corresponding Author

How to cite this article: Samajdar SS, Chatterjee R, Mukherjee S, et al. Ribavirin and IVIG Therapy for Severe hMPV Pneumonia: A Promising Therapeutic Approach for India. *J Assoc Physicians India* 2025;73(9):98–100.

exerts immunomodulatory effects by downregulating proinflammatory cytokines such as tumor necrosis factor alpha (TNF- α) and interleukin-10 (IL-10), thereby mitigating the excessive inflammatory responses associated with severe respiratory infections.⁷

Intravenous Immunoglobulin

Intravenous immunoglobulin provides passive immunity by neutralizing hMPV and supporting antibody-dependent cellular cytotoxicity (ADCC). IVIG enhances the host's ability to clear viral infections, making it particularly effective in immunocompromised patients with diminished endogenous antibody production. The complementary mechanisms of ribavirin and IVIG contribute to their synergistic efficacy in controlling severe hMPV infections.⁸

Barriers to Implementation in India

Cost and Accessibility

Ribavirin and IVIG remain prohibitively expensive in many parts of India, posing a significant barrier to their widespread use. Their availability is often limited to tertiary care centers, making them inaccessible to patients in resource-limited settings.

Lack of Awareness

The use of ribavirin–IVIG for severe hMPV is not widely recognized among Indian clinicians, contributing to its underutilization. Awareness campaigns and training programs are needed to bridge this knowledge gap.

Evidence Gaps

A lack of robust, large-scale randomized controlled trials (RCTs) specific to Indian populations impedes the development of standardized treatment guidelines. Local studies are crucial to establish the efficacy, optimal dosing, and cost-effectiveness of this combination therapy in the Indian healthcare context.

By addressing these barriers, ribavirin–IVIG therapy could become an integral part of managing severe hMPV pneumonia in India, particularly for high-risk populations.

Discussion

Potential Benefits in the Indian Context

India bears a substantial burden of respiratory infections, driven by a high prevalence of comorbidities such as malnutrition, chronic respiratory diseases, and immunosuppressive conditions including cancer and

posttransplant immunosuppression. Severe cases of hMPV pneumonia, particularly in these high-risk groups, are associated with significant morbidity and mortality.

Ribavirin and IVIG therapy offers a dual-targeted approach that addresses both the viral burden and the compromised immune response in these populations. Ribavirin's antiviral action directly suppresses hMPV replication, while IVIG provides passive immunity, neutralizing the virus and enhancing immune clearance. Integrating this combination therapy into clinical practice could dramatically improve outcomes for patients with severe hMPV, reducing hospitalization duration and mortality rates. Furthermore, by mitigating disease severity, ribavirin–IVIG therapy has the potential to ease the burden on India's overstressed critical care infrastructure, especially during respiratory infection surges.⁹

Implementation Challenges

Despite its promise, several barriers hinder the widespread adoption of ribavirin–IVIG therapy in India:

- **Cost and accessibility:** Ribavirin and IVIG are costly, with availability largely confined to tertiary care hospitals in urban areas. This limits access for patients in rural or resource-limited settings. Government-subsidized healthcare programs, along with partnerships between public health authorities and pharmaceutical manufacturers, could reduce the financial burden on patients and healthcare systems. Local production of ribavirin and IVIG may also help lower costs.
- **Awareness and training:** Limited awareness among healthcare professionals regarding the use of ribavirin–IVIG for severe hMPV cases is a significant barrier. Evidence-based guidelines and clinician training programs are urgently needed to promote the judicious and effective use of this therapy. Awareness campaigns targeting both tertiary and secondary care centers can bridge this knowledge gap.
- **Logistical challenges:** Storage, distribution, and administration of ribavirin and IVIG require infrastructure that is often unavailable in smaller healthcare facilities. Strengthening supply chain logistics and ensuring timely availability of these drugs are critical to their successful implementation.

Research Directions

To integrate ribavirin–IVIG therapy into routine care for severe hMPV pneumonia in

India, robust evidence from local clinical trials is essential. Future research should focus on:

- **Efficacy:** Conducting multicenter RCTs to establish the effectiveness of ribavirin–IVIG therapy in reducing mortality and improving recovery in severe hMPV cases.
- **Optimal dosing and timing:** Evaluating the most effective dosing regimens and timing of administration to maximize clinical outcomes while minimizing adverse effects.
- **Cost-effectiveness:** Investigating the economic feasibility of ribavirin–IVIG therapy in resource-constrained settings, including strategies to optimize drug procurement and reduce costs.
- **Subpopulation analysis:** Assessing the therapy's impact on different patient subgroups, such as pediatric, geriatric, and oncology patients, to develop tailored treatment protocols.

By addressing these research gaps, India can establish evidence-based guidelines for the use of ribavirin and IVIG, paving the way for wider adoption of this promising therapy.

Conclusion

The combination of ribavirin and IVIG represents a targeted and effective therapy for severe hMPV pneumonia, particularly in immunocompromised populations. While challenges such as cost, awareness, and infrastructure limit its current applicability, strategic interventions can overcome these barriers. Government initiatives, public–private collaborations, and clinician education are critical to making this therapy accessible to those who need it most.

Prioritizing research through multicenter trials and collaborative efforts will strengthen the evidence base, enabling India to integrate ribavirin–IVIG therapy into standard care protocols. By doing so, the country can enhance clinical outcomes, reduce the burden of respiratory infections, and improve the quality of life for vulnerable patients.

ORCID

Shatavisa Mukherjee  <https://orcid.org/0000-0001-9524-1525>

Nandini Chatterjee  <https://orcid.org/0000-0002-7729-812X>

Jyotirmoy Pal  <https://orcid.org/0000-0001-7769-9655>

Mangesh Tiwaskar  <https://orcid.org/0000-0003-4024-0095>

Shashank Joshi  <https://orcid.org/0000-0003-2741-5022>

REFERENCES

1. Hamelin ME, Abed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. *Clin Infect Dis* 2004;38(7):983–990.
2. Rao BL, Gandhe SS, Pawar SD, et al. First detection of human metapneumovirus in children with acute respiratory infection in India: a preliminary report. *J Clin Microbiol* 2004;42(12):5961–5962.
3. El Chaer F, Shah DP, Kmeid J, et al. Burden of human metapneumovirus infections in patients with cancer: risk factors and outcomes. *Cancer* 2017;123(12):2329–2337.
4. Kitanovski L, Kopriva S, Pokorn M, et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. *J Pediatr Hematol Oncol* 2013;35(7):e311–e313.
5. Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. *Clin Infect Dis* 2019;68(10):1641–1649.
6. Tejada S, Martinez-Reviejo R, Karakoc HN, et al. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. *Adv Ther* 2022;39(9):4037–4051.
7. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. *Rev Med Virol* 2006;16(1):37–48.
8. Simon HU, Späth PJ. IVIG—mechanisms of action. *Allergy* 2003;58(7):543–552.
9. Shachor-Meyouhas Y, Ben-Barak A, Kassir I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. *Pediatr Blood Cancer* 2011;57(2):350–351.



UPDATE MOBILE NUMBER / EMAIL ID

Members are requested to update their address, mobile numbers and email ID.

All are requested to send the above details to the Hon. General Secretary of API for postage of JAPI, API communications by email to api.hdo@gmail.com.

Dr. Agam C Vora
Hon. General Secretary